Abstract
Human immunodeficiency virus type I (HIV-1), a causative agent of AIDS, is affecting today more than 35 millions of people worldwide. The advance of anti-HIV chemotherapy has made AIDS a chronic non-fatal disease in resourceful countries. Long-awaited anti-HIV-1 vaccine is still not with us yet; however, great progress in structural analyses of the envelope protein of HIV-1 in recent years starts to shed light on rational intervention targeted at the envelope protein, as will be reviewed in this article.
MeSH terms
-
AIDS Vaccines / immunology
-
Antibodies, Neutralizing / immunology
-
HIV Antibodies / immunology
-
HIV-1 / chemistry*
-
HIV-1 / genetics
-
HIV-1 / immunology
-
Host-Pathogen Interactions / immunology
-
Humans
-
Membrane Fusion
-
Models, Molecular
-
Mutation
-
Protein Conformation
-
env Gene Products, Human Immunodeficiency Virus / chemistry*
-
env Gene Products, Human Immunodeficiency Virus / genetics
Substances
-
AIDS Vaccines
-
Antibodies, Neutralizing
-
HIV Antibodies
-
env Gene Products, Human Immunodeficiency Virus